1 withdrawn. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow David Bushnell: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors Lutathera, Azedra - Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors | Phase 1 / Phase 2 | Withdrawn | David Bushnell | 2022-09-30 | 2024-04-29 |
Gastro-enteropancreatic neuroendocrine tumor (1) · Neuroendocrine Tumors (1)
3-Iodobenzylguanidine (1) · lutetium Lu 177 dotatate (1)
United States (1)
P50CA174521 (1)